Partnering & Licensing

Applying a virtual model, Isarna is pursuing a broad portfolio of TGF-β inhibitors in a range of indications. With clinical development of our lead compound progressing in ophthalmology and a broad potential of our approach in other indications, Isarna is open for partnering discussions aimed to drive current and future applications of the combined TGF-β and antisense oligonucleotide platform forward.

Contact information: